

OTCQB Certification

I, M. Scott Maguire, CEO of Xenetic Biosciences, Inc. ("the Company"), certify that:

- a. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below (check one):
- ☐ Company is registered under Section 12(g) of the Exchange Act
 - ☐ Company is relying on Exchange Act Rule 12g3-2(b)
 - ☐ Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
 - ☐ Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
 - ☐ Company is reporting under Section 15(d) of the Exchange Act.
 - ☒ Other (describe) Voluntary Filer
- b. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC's EDGAR system or the OTC Disclosure & News Service, as applicable.
- c. The Company Profile displayed on www.otcmarkets.com is current and complete as of June 10, 2016, and includes the total shares outstanding, authorized, and in the public float as of that date.
- d. The following is a complete list of attorney(s) and law firm(s) who advised or assisted in the preparation of the Company's most recent annual report, including in-house counsel: (If no attorney assisted in putting together the disclosure, indicate the person or persons who prepared the disclosure and their relationship to the company.)

Westward Law LLC

Taft Stettinius & Hollister LLP

Kleinfeld, Kaplan & Becker LLP

- e. The following is a complete list of third party providers, including names and addresses, engaged by the Company, its officers, directors or controlling shareholders, during the period from the Company's prior fiscal year end to the date of this OTCQB Certification, to provide investor relations services, public relations services, or other related services to the Company including promotion of the Company or its securities:

Jenene Thomas Communications, 48 Sky Manor Rd, Pittstown, NJ 08867

Lippert / Heilshorn & Associates, Inc, 800 Third Avenue, 17th Floor, New York, NY 10022

Arlington Group Asset Management Limited, 18 Pall Mall, London, UK SW1Y 5LU

MDM Worldwide Solutions, 264 West 40th Street, Suite 602, New York, NY 10018

Chesapeake Group, Inc., 305 Washington Ave., Ste. 100, Towson, MD 21204

Ladenburg Thalmann & Co. Inc., 4400 Biscayne Blvd, Miami, FL 33137

Donohoe Advisory Associates LLC, 9901 Belward Campus Drive Suite 175, Rockville, MD 20850

- f. Listed below are the names, legal addresses and % of shares owned by all Officers, Directors and Control Persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities). If any of the beneficial shareholders are corporate shareholders, the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders must also be included.

Name	Address (City and State only)	% Shares Owned
PJSC Pharmsynthez (Dr. Dmitry Genkin, Chairman)	St Petersburg, Russian Federation	52.2% beneficial ownership
SynBio LLC (Roman Knyazev, Director)	Moscow, Russian Federation	20.9% beneficial ownership
Baxalta Inc.(Flemming Ornskov, Shire plc CEO)	Bannaockburn, IL	5.6% beneficial ownership

Serum Institute of India Ltd (Cyrus Poonawalla, Chairman)	Pune, India	7.5% beneficial ownership
M. Scott Maguire (CEO, Director)	Lexington, MA	4.5% beneficial ownership
Firdaus Dastoor (Director)	Lexington, MA	*
Darlene Deptula-Hicks (Director)	Lexington, MA	*
Dr. Roger Kornberg (Director)	Lexington, MA	*
Roman Knyazev (Director)	Lexington, MA	*
		*Beneficial ownership less than one percent

Date: June 24, 2016

Name of Certifying CEO or CFO: M. Scott Maguire

Title: Chief Executive Officer

Signature: /s/ Michael Scott Maguire
 (Digital Signatures should appear as "/s/ [OFFICER NAME]")